Aptus Endosystems is a privately held Sunnyvale, Calif. medical device company focused on developing advanced technology for endovascular aneurysm repair (EVAR). Its products include the HeliFX Aortic Securement System, which is cleared by the U.S. FDA and bears a CE Mark, and the Fortevo AAA Endograft System, which has a CE Mark and is investigational in the United States. The company has developed a unique endograft and helical anchor technology intended to enable minimally invasive EVAR while providing control and potential long-term durability. Proceeds from the financing will be used to expand commercialization of HeliFX in the United States and Europe, develop additional HeliFX product offerings, execute a U.S. clinical trial of the Fortevo system to support a Premarket Approval filing with the FDA, and expand Fortevo utilization in key European centers. Management stated the capital will be used judiciously to grow product use, introduce new aortic repair products, and approach profitability. Aptus Endosystems is a Sunnyvale, Calif. biotech company developing the Abdominal Aortic Aneurysm Repair System, a device designed to fix abdominal aneurysms. The company is using the funding to finish clinical trials of the repair system. Management says the $30 million round should cover a U.S. launch in 2010 and a smaller release in Europe. Aptus previously raised $19.5 million in 2006 to advance the device through early trial phases. The company’s near-term plans center on completing trials and bringing the product to market in the U.S. and Europe. Financially, the new third-round financing is positioned to support those commercialization milestones.

Total raised

$55M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2012